Buzz Stocks: Apollo Education Group Inc, GoPro Inc, and BioCryst Pharmaceuticals, Inc.

Today's stocks to watch include Apollo Education Group Inc (APOL), GoPro Inc (GPRO), and BioCryst Pharmaceuticals, Inc. (BCRX)

Feb 8, 2016 at 9:29 AM
facebook X logo linkedin


Today is setting up to be a brutal session on Wall Street, with a number of major tech names selling off in electronic trading. Elsewhere, University of Phoenix parent Apollo Education Group Inc (NASDAQ:APOL), camera concern GoPro Inc (NASDAQ:GPRO), and drugmaker BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) are among the stocks to watch.

  • APOL is soaring on news the company will be taken private in a $1.1 billion deal with a consortium of investors, including private equity firm Apollo Global Management LLC (NYSE:APO). Specifically, the shares have added 27.6% pre-market, after closing Friday at $6.95 -- down 73% year-over-year. On Wall Street, Apollo Education Group Inc has been met with skepticism by analysts, as all six covering brokerage firms have handed out a "hold" or "sell" rating.

  • GPRO has tacked on 4.4% in electronic trading, after the company inked a patent licensing agreement with Microsoft Corporation (NASDAQ:MSFT). A day in the green would be welcomed by GoPro Inc shareholders, who watched the stock hit an all-time low of $9.01 as recently Feb. 4 following a surprise quarterly loss. Longer term, the shares have shed 85% since their annual high of $65.49 in August to land at $9.96. Not surprisingly, traders at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) have been placing bearish bets over bullish at a rapid rate. GPRO's 10-day put/call volume ratio of 0.72 outstrips four-fifths of comparable readings taken in the last year. As such, the stock could benefit if these pessimists hit the exits amid a resurgence in the shares. 

  • BCRX is bracing for a 62.5% fall at the open, after the firm said its lead drug to treat swelling in patients with hereditary angiodema failed a late-stage trial. As such, the stock -- which closed at $6.14 on Friday -- is primed to open at a more than two-year low. This is a great development for option bears, who have been busy at the ISE, CBOE, and PHLX in recent weeks. Specifically, BioCryst Pharmaceuticals, Inc.'s 10-day put/call volume ratio of 9.49 ranks just 2 percentage points from an annual high.
Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI